129 results
Page 2 of 7
6-K
EX-99.2
25qh9pzaxc 402u48
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.1
7zhzt
4 Aug 22
Current report (foreign)
11:41am
6-K
EX-99.2
q9z8rsa1559k52k8x
4 Aug 22
Current report (foreign)
11:41am
6-K
EX-99.1
o4e q6ib0uv7j07a6l
28 Jul 22
Current report (foreign)
2:52pm
6-K
EX-99
hr2efdm
26 Jul 22
Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
1:45pm
6-K
EX-99.1
t1ix yvlusaf34l
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.4
ylvimngh
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.4
ugak890b4wr4 9tjsu1c
10 May 22
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
4:34pm
6-K
EX-99.3
egltzg stzpu
10 May 22
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
4:34pm
6-K
EX-99.1
kfzdptk5i1y 9meh5
29 Mar 22
RepliCel Announces Non-brokered Private Placement
1:02pm
6-K
EX-99.1
1etato
29 Mar 22
RepliCel Announces Material Patent Milestones
12:51pm
6-K
EX-99.2
lwyyodjg0li
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
hb8 udj65a7mirb
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.1
8dkbbfnhs rx
2 Nov 21
RepliCel Announces Dermal Injector Update
12:31pm
6-K
EX-99.1
rmbmg1 qtni5f0h
14 Oct 21
51-102F3 Material Change Report
4:00pm
6-K
EX-99.1
2karvuu
13 Oct 21
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
12:00am
6-K
EX-99.2
cmp4r7za96udlkb
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
r8vdh
18 Aug 21
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
12:38pm
6-K
EX-99.4
z64gf6im
18 Aug 21
Current report (foreign)
12:20pm